Literature DB >> 9673862

Highly precise peripheral quantitative computed tomography for the evaluation of bone density, loss of bone density and structures. Consequences for prophylaxis and treatment.

M A Dambacher1, M Neff, R Kissling, L Qin.   

Abstract

The importance of serial examinations over time with peripheral quantitative computed tomography (pQCT) is that they enable the detection of patients at high risk of osteoporosis, and the individualisation of prophylaxis and treatment. We have shown that postmenopausal patients with high bone turnover evaluated by biochemical markers are identical to fast bone losers as determined by pQCT. As a consequence, we use agents that inhibit bone resorption in patients who are fast bone losers and agents that stimulate bone formation in patients who are slow bone losers. To visualise bone microarchitecture, and to evaluate bone density and the rate of bone loss, we used a highly sensitive pQCT system (DENSISCAN 1000, reproducibility of 0.3% in a mixed population of normal individuals and patients with osteopenia or osteoporosis). This system enabled us to separately assess trabecular and cortical bone density in the radius and tibia, and to differentiate between fast and slow bone losers within a few months (threshold: 3% loss of trabecular bone density in the radius per year). We have shown that the lower the trabecular bone density in the distal radius, the higher the relative bone loss. To classify patients as slow and fast losers in the future, we may need only one measurement. With this highly precise measurement method, we have shown that calcitonin and etidronate are more effective in fast than in slow bone losers, and that vitamin D metabolites (calcitriol or 1 alpha-calcidol) and estrogens can halt fast bone loss. In conclusion, highly sensitive pQCT enables us to adapt the treatment to different forms of osteoporosis and bone turnover, resulting in an increase in the number of patients successfully treated and also in patient compliance. Because our treatment is based on precise, objective measurements, treatment modifications--especially in those who change from a slow to a fast bone-loser state--can be easily justified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9673862     DOI: 10.2165/00002512-199812001-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  10 in total

1.  The effect of overlying calcification on lumbar bone densitometry.

Authors:  P J Drinka; A A DeSmet; S F Bauwens; A Rogot
Journal:  Calcif Tissue Int       Date:  1992-06       Impact factor: 4.333

2.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Authors:  T Storm; G Thamsborg; T Steiniche; H K Genant; O H Sørensen
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

3.  Influence of fat on bone measurements with dual-energy absorptiometry.

Authors:  T N Hangartner; C C Johnston
Journal:  Bone Miner       Date:  1990-04

4.  The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis.

Authors:  S Gonnelli; C Cepollaro; C Pondrelli; S Martini; R Monaco; C Gennari
Journal:  J Bone Miner Res       Date:  1997-04       Impact factor: 6.741

5.  Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.

Authors:  P Garnero; E Hausherr; M C Chapuy; C Marcelli; H Grandjean; C Muller; C Cormier; G Bréart; P J Meunier; P D Delmas
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

6.  [Loss of bone mass in patients with anorexia on tube feeding and its prevention with biphosphonates].

Authors:  H G Kopp; P Rüegsegger; M A Dambacher
Journal:  Schweiz Med Wochenschr       Date:  1992-04-11

7.  Long-term fluoride therapy of postmenopausal osteoporosis.

Authors:  M A Dambacher; J Ittner; P Ruegsegger
Journal:  Bone       Date:  1986       Impact factor: 4.398

8.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

9.  Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes.

Authors:  B L Riggs; H W Wahner; E Seeman; K P Offord; W L Dunn; R B Mazess; K A Johnson; L J Melton
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

10.  Peripheral QCT: a low-risk procedure to identify women predisposed to osteoporosis.

Authors:  A Müller; E Rüegsegger; P Rüegsegger
Journal:  Phys Med Biol       Date:  1989-06       Impact factor: 3.609

  10 in total
  6 in total

Review 1.  Fast and slow bone losers. Relevance to the management of osteoporosis.

Authors:  S Hough
Journal:  Drugs Aging       Date:  1998       Impact factor: 3.923

Review 2.  Is bone tissue really affected by swimming? A systematic review.

Authors:  Alejandro Gómez-Bruton; Alejandro Gónzalez-Agüero; Alba Gómez-Cabello; José A Casajús; Germán Vicente-Rodríguez
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

3.  Bone density measurements in pediatric patients with renal osteodystrophy.

Authors:  Eleonora M Lima; William G Goodman; Beatriz D Kuizon; Barbara Gales; Aletha Emerick; Jonathan Goldin; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2003-04-24       Impact factor: 3.714

4.  Proximal tibia volumetric bone mineral density is correlated to the magnitude of local acceleration in male long-distance runners.

Authors:  Olivier Dériaz; Bijan Najafi; Pierluigi Ballabeni; Antoinette Crettenand; Charles Gobelet; Kamiar Aminian; René Rizzoli; Gerald Gremion
Journal:  J Appl Physiol (1985)       Date:  2010-02-04

5.  Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women.

Authors:  Kenjiro Sawada; Ken-Ichirou Morishige; Yukihiro Nishio; Jun Hayakawa; Seiji Mabuchi; Aki Isobe; Seiji Ogata; Masahiro Sakata; Masahide Ohmichi; Tadashi Kimura
Journal:  J Bone Miner Metab       Date:  2009-01-20       Impact factor: 2.626

6.  A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men.

Authors:  B Lawrence Riggs; L Joseph Melton; Richard A Robb; Jon J Camp; Elizabeth J Atkinson; Lisa McDaniel; Shreyasee Amin; Peggy A Rouleau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2008-02       Impact factor: 6.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.